StreetInsider.com News Articles

Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat

Tue, 02 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26593802.html

Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat

Tue, 02 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26593802.html

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat

Mon, 01 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260601/26583761.html

Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat

Mon, 01 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260601/26583761.html

Dianthus Therapeutics to Participate in Two Investor Conferences

Tue, 26 May 2026 16:01:00 -0400

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in two investor conferences in June 2026.

Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, will participate in a fireside chat on Wednesday, June 3, 2026, at 12:45 p.m. ET and will host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference.

Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday,

Dianthus Therapeutics to Participate in Two Investor Conferences

Tue, 26 May 2026 16:01:00 -0400

Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday,

Dianthus Therapeutics to Participate in Two Investor Conferences

Tue, 26 May 2026 16:01:00 -0400

Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday,

Dianthus Therapeutics to Participate in Two Investor Conferences

Tue, 26 May 2026 16:01:00 -0400

Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday,

Form 4 Dianthus Therapeutics, For: May 21 Filed by: KANGO SUJAY